Combination therapy with midostaurin improves survival of acute myeloid leukemia patients with FLT3 mutations, phase 1

A targeted drug that is active against acute myeloid leukemia is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, according to new research.